Enzyme inhibitor examples for the treatment of prostate tumor

Enzymes and their Inhibitors: Drug Development

Volumn , Issue , 2004, Pages 241-253

  Haidar, Samer ^a   Hartmann, Rolf W ^a  

^a Department of NDT and Quality Assurance Saar University Campus E3 1   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37549054422     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (48)

1. Andersson, S. and Russell, D.W. (1990). Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductase. Proceedings of the National Academy of Sciences U.S. A., 87, 3640-3644.
2. Bartsch, G., Rittmaster, R.S., and Klocker, H. (2000). Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign hyperplasia. European Urology, 37, 367-380.
3. McConnell, J.D. (1990). Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urological Clinics of North America, 17, 661-670.
4. Thiboutot, D.M., Gilliland, K.B., Light, J.L., and Lookingbill, D.M. (1999). Androgen metabolism in sebaceous glands from subjects with and without acne. Archive of Dermatology, 135, 1041-1045.
5. Inhibitors of 5α-Reductase Audet, P., Nurcombe, H., Lamb, Y., Jorkasky, D., Loyd-Davies, K., and Morris, R. (1993). Effect of multiple doses of epristeride (E) a steroidal 5α-reductase inhibitor on serum dihydrotestosterone (DHT) in older male subjects. Clinical Pharmacology and Therapeutics, 53, 231.
6. Bramson, H.N., Hermann, D., Batchelor, K.W., Lee, F.W., James, M.K., and Frye, S.V. (1997). Unique preclinical characteristics of GG745, a potent dual inhibitor of 5α-reductase. Journal of Pharmacology and Experimental Therapeutics, 282, 1486-1502.
7. Chapelsky, M.C., Nicholas, A., Jorkasky, D.K., Lundberg, D.E., Knox, S.H., and Audet, P.R. (1992). Pharmacodynamics of SK&F105657 in healthy male subjects. Clinical Pharmacology and Therapeutics, 51, 154.
8. Coltman, C.A., Thompson, I.M. and Feigl, P. (1999). Prostate cancer prevention trial (PCPT) update. European Urology, 35, 544-547.
9. Cooper, K.L., McKiernan, J.M., and Kaplan, S.A. (1999). α-Adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs, 57, 9-17.
10. Frye, S.V. (1996). Inhibitors of 5α-reductase. Current Pharmaceutical Design, 2, 59-84.
11. Graul, A., Silvestre, J., and Castaner, J. (1999). Dutasteride. Drugs of the Future, 24, 246-324.
12. Hirosumi, J., Nakayama, O., Chida, N., Inami, M., Fagan, T., Sawada, K., Shigematsu, S., Kojo, H., Notsu, Y., and Okuhara, M. (1995). FK143, a novel nonsteroidal inhibitor of steroid 5a-reductase: (2) In viv effects on rat and dog prostate. Journal of Steroid Biochemistry and Molecular Biology, 52, 365-373.
13. Hobbs, S., Hermann, D.J., Gabriel, T., Wilson, B., Morrill, R., and Clark, R.V. (1998). Marked suppression of dihydrotestosterone in men by novel 5 alpha reductase inhibitor. Fertility and Sterility, 70 (Suppl. 3), 4555.
14. Holt, D.A., Yamashita, D.S., Konialian-Beck, A.L., Luengo, J.I., Abell, A.D., Bergsam, D.J., Brandt, M., and Levy, M.A. (1995). Benzophenone and indolecarboxylic acids: Potent type 2 specific inhibitors of human steroid 5α-reductase. Journal of Medicinal Chemistry, 38, 13-15.
15. Levy, M.A., Brandt, M., Sheedy, K.M., Dinh, J.T., Holt, D.A., Garrison, L.M., Bergsma, D.J., and Metcalf, B.W. (1994). Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5α-reductase isoform 2. Journal of Steroid Biochemistry and Molecular Biology, 48, 197-206.
16. Li, X., Chen, C., Singh, M., and Labrie, F. (1995). The enzyme and inhibitors of 4-ene-3- oxosteroid 5α-oxidoreductase. Steroids, 60, 430-441.
17. McCellan, K.J. and Markham, A. (1999). Finasteride: a review of its use in male pattern hair loss. Drugs, 57, 111-126.
18. McConnell, J.D., Wilson, J.D., George, F.W., Geller, J., Pappas, F., and Stoner, E. (1992). Finasteride, an inhibitor of 5 alpha reductase suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. The Journal of Clinical Endocrinology & Metabolism, 74, 505-508.
19. McNulty, A.M., Audia, J.E., Bemis, K.G., Goode, R.L., Rocco, V.P., and Neubauer, B.L. (2000). Kinetic analysis of LY320236: competitive inhibitor of type I and noncompetitive inhibitor of type II human steroid 5α-reductase. Journal of Steroid Biochemistry and Molecular Biology, 72, 13-21.
20. Norman, R.W., Coakes, K.E., Wright, A.S., and Rittmaster, R. (1993). Androgen metabolism in men receiving finasteride before prostatectomy. Journal of Urology, 150, 1736-1739.
21. Picard, F., Barassin, S., Mokhtarian, A., and Hartmann, R.W. (2003). Synthesis and evaluation of 2`-substituted 4-(4`-carboxy- or 4`-carboxymethylbenzylidene)-N-acylpiperidines:Highly potent and in vivo active steroid 5α-reductase type 2 inhibitors. Journal of Medicinal Chemistry, 45, 3406-3417.
22. Picard, F., Schulz, T., and Hartmann, R.W. (2002). 5-Phenyl substituted 1-methyl-2-pyridones and 4-substituted biphenyl-4`-carboxylic acids. Synthesis and evaluation as inhibitors of steroid-5 alpha-reductase type 1 and 2. Bioorganic Medicinal Chemistry, 10, 437-448.
23. Rasmusson, G.H., Johnston, D.B., and Arth, G.E. (1983). 4-Aza-17-substituted 5α-androstan-3-one reductase inhibitors. International patent application U.S. 4,377,584, March 22.
24. Rasmusson, G.H., Johnston, D.B., Reinhold, D.F., Utne, T., and Jobson, R.B. (1980). Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors. International patent application U.S. 4,220,775, September 2.
25. Steiner, F. (1996). Clinical pharmacokinetics and pharmacodynamics of finasteride. Clinical Pharmacokinetics, 30, 16-27.
26. Zaccheo, T., Giudici, D., and DiSalle, E. (1997). Effect of turosteride, a 5 alpha reductase inhibitor on the Dunning R3327 rat prostatic carcinoma. Prostate, 30, 85-91.
27. Akhtar, M., Corina, D., Miller, S., Shyadehi, A.Z., and Wright, N. (1994). Mechanism of the acyl-carbon cleavage and related reactions catalyzed by multifunctional P-450s: studies on cytochrome P450 17. Biochemistry, 33, 4410-4418.
28. De Coster, R., Wouters, W., and Bruynseels, J. (1996). P 450-dependent enzymes as targets for prostate cancer therapy. Journal of Steroid Biochemistry and Molecular Biology, 56, 133-143.
29. Hartmann, R.W., Ehmer, P.B., Haidar, S., Hector, M., Jose, J., Klein, C.D.P., Seidel, S., Sergejew, T.F., Wachall, B.G., Wächter, G.A., and Zhuang, Y. (2002). Inhibition of CYP 17, a new strategy for the treatment of prostate cancer. Archive Der Pharmazie, Pharmaceutical and Medicinal Chemistry, 33, 119-128.
30. Huggins, C. and Hodges, C.V. (1941). Studies of prostate cancer. The effects of castration, of estrogen and androgen injections on serum phosphatases in metastatic carcinoma of prostate. Cancer Research, 1, 293-307.
31. Nakajin, S., Shively, J.E., Yuan, P.M., and Hall, P.F. (1981). Microsomal cytochrome P450 from neonatal pig testis: Two enzymatic activities (17 α-hydroxylase and C17, 20- lyase) associated with one protein. Biochemistry, 20, 4037-4042.
32. Njar, V.C.O. and Brodie, A.M.H. (1999). Inhibitors of 17α-hydroxylase/17, 20-lyase (CYP 17): potential agents for the treatment of prostate cancer. Current Pharmaceutical Design, 5, 163-180.
33. Angelastro, M.R., Laughlin, M.E., Schatzman, G.L., Bey, P., and Blohm, R. (1989). 17 (cyclopropylamino)androsta-5-en-3-ol, as a selective mechanism-based inhibitor of cytochrome P450 17 (steroid 17α-hydroxylase/C 17-20-lyase). Biochemical and Biophysical Research Communications, 162, 1571-1577.
34. Ayub, M. and Levell, M. (1987). Inhibition of testicular 17 alpha-hydroxylase and 17, 20- lyase but not 3 beta-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs. Journal of Steroid Biochemistry, 28, 521-531.
35. Barrie, S.E., Haynes, B.P., Potter, G.A., Chan, F.C.Y., Coddard, P.M., Dowsett, M., and Jarman, M. (1996). Biochemistry and pharmacokinetics of potent nonsteroidal cytochrome P450 17α?inhibitors. Journal of Steroid Biochemistry and Molecular Biology, 60, 347-351.
36. Haidar, S., Ehmer, P.B., Barassin, S., Batzl-Hartmann, C., and Hartmann, R.W. (2003). Effects of novel 17α-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. Journal of Steroid Biochemistry and Molecular Biology, 84, 555-562.
37. Hartmann, R.W., Hector, M., Haidar, S., Ehmer, P.B., Reichert, W., and Jose, J. (2000). Synthesis and evaluation of novel steroidal oxime inhibitors of P 450 17 (17α- hydroxlase/C 17-20-lyase) and 5α-reductase types 1 and 2. Journal of Medicinal Chemistry, 43, 4266-4277.
38. Hartmann, R.W., Wachall, B.G., Yoshihama, M., Nakakoshi, M., Nomoto, S., and Ikeda, Y. (2002). Novel dihydronaphthalene compounds and processes of producing the same. U.S. patent US 2002/0032211 A1.
39. Higashi, Y., Omura, M., Suzuki, K., Inano, H., and Oshima, H. (1987). Ketoconazole as a possible universal inhibitor of cytochrome P450 dependent enzymes: its mode of inhibition. Endocrinologia Japonica, 34, 8105-8115.
40. Ideyama, Y., Kudoh, M., Tanimoto, K., Susaki, Y., Nanya, T., Nakahara, T., Ishikawa, H., Yoden, T., Okada, M., Fujikura, T., Akaza, H., and Shikama, H. (1998). Novel nonsteroidal inhibitor of cytochrome P450 17 (17α-hydroxylase-C17-20-lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats. Prostate, 37, 10-18.
41. Ideyama, Y., Kudoh, M., Tanimoto, K., Susaki, Y., Nanya, T., Nakahara, T., Ishikawa, H., Fujikura, T., Akaza, H., and Shikama, H. (1999). YM 116, 2-(1H-Imidazole-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells. Japan Journal of Pharmacology, 79, 213-220.
42. Klus, G.T., Nakamura, J., Li, J-S., Ling, Y-Z., Son, C., Kemppainen, A., Wilson, E.M., and Brodie, A.M.H. (1996). Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Cancer Research, 56, 4956-4964.
43. Neubauer, B.L., Best, K.L., Blohm, T.R., Gast, C., Goode, R.L., Hirsch, K.S., Laughlin, M.E., Petrow, V., Smalstig, E.B., Stamm, N.B., Toomey, R.E., and Hoover, D. (1993). LY207320 (6-Methylene-4-pregnene-3,20-dione) inhibits testosterone biosynthesis, androgen uptake, 5α-reductase, and produces prostatic regression in male rats. Prostate, 23, 181-199.
44. Nnane, P., Long, B.J., Ling, Y-Z., Grigoryev, D.N., and Brodie, A.M. (2000). Anti-tumor effects and pharmacokinetic profile of 17-(5-isoxazolyl) androsta-4, 16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis. British Journal of Cancer, 83, 74-82.
45. Potter, G.A., Barrie, E.S., Jarman, M., and Rowlands, M.G. (1995). Novel steroidal inhibitors of human cytochrome P450 17α: potential agents for the treatment of prostatic cancer. Journal of Medicinal Chemistry, 38, 2463-2471.
46. Trachtenberg, J., Halpern, N., and Pont, A. (1984). Ketoconazole: A novel and rapid treatment for advanced prostatic cancer. Journal of Urology, 132, 61-63.
47. Wachall, B.W., Hector, M., Zhuang, Y., and Hartmann, R.W. (1999). Imidazole substituted biphenyls - a new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer. Bioorganic and Medicinal Chemistry, 7, 1913-1924.
48. Zhuang, Y., Wachall, B.W., and Hartmann, R.W. (2000). Novel imidazolyl and triazolyl biphenyl compounds: synthesis and evaluation as nonsteroidal inhibitors of human 17α-hydroxylase-C17, 20-lyase (P450 17). Bioorganic and Medicinal Chemistry, 8, 1245-1252.